I INTRODUCE YOU ---- ICC LABS THE SLEEPING GIANT
GMP SECURITIES PRICE TARGET 3.25
FDITM Shares Outstanding 122M
• They are focused on becoming worldwide leaders in the production of CBD extracts for medicinal purposes.
• Total outdoor acreage available for CBD-strain production is now 680 acres.
• Total greenhouse area for THC-strain production is expected to reach 200,000 sq. ft. With the colombian facility and excluding their february 7 2018 application for new 1 million square foot greenhouse.
• They have an extraction laboratory currently being constructed with state of the art technology located in Canelones, Uruguay, with an expected processing throughput of 150,000 kilograms of dried flowers per year.
• ON FEBRUARY 7 2018 ICC LABS ANNOUNCES APPLICATION FOR REGULATORY APPROVAL FOR NEW 1 MILLION SQUARE FOOT GREENHOUSE .
• ICC Labs Inc. Largest Shareholder( Union Group) is a privately owned, multi- billion dollar conglomerate, which holds various strategic interests in the Latin American Agriculture, forestry, infrastructure, minerals, oils and gas, and real estate sectors.
_____________________________________________________________
SUPERIOR REGULATORY ENVIRONMENT
• Uruguay’s regulations for industrial hemp farming provide significant advantage over competitors :Hemp strains with CBD content in excess of 10.0%
• Canada: rgulations restrict yields to 0.3% - 0.4%
• Europe: hemp yields average 3.0% - 4.0%
• Production costs average $4/gram of CBD extract in comparison to Canadian LPs who average $20-30/gram
_____________________________________________________________
• The government of Uruguay has only awarded two production licenses in Uruguay. Not only is ICC the dominant producer for the domestic market but the Company is the only producer for medicinal cannabis exports.
• On November 23 they announced a pre-sale agreement with a Brazilian counter-party to export 180.000 “30mmL” bottles of ICC’s newly launched, propietary line of CBD oil branded “BIDIOL” in 2018.
• On October 19th they announced a pre-sale agreement with a Mexican counter-party to export 10% of our CBD oil production in 2018. They expect to produce 1.2 million “30mmL” bottles of CBD oil in 2018.
• Emblem: Presale of the 10% of ICC Labs Inc.’s CBD production in 2018.
• Nuuvera: Sale of 150 kg of pure CBD with a pre-payment of US dollars $ 150.000.
• ICC LABS INC. RECEIVES MEDICINAL CANNABIS LICENSE IN COLOMBIA
• ICC Labs expects to commence licensed outdoor planting of non-psychoactive cannabis seeds on 250 acres of land the Company has secured.
• The Company expects to commence the construction of a 124,000 sq. ft. Greenhouse in colombia.
• ICC LABS SIGNS TERM SHEET TO ACQUIRE EQUITY STAKE (25%) IN STRATEGIC PARTNER WITH KALAPA AND ENTER THE EUROPEAN MARKET
• Access to five important European markets: Germany, United Kingdom, Spain, Italy and France.
• Use of an ESTABLISHED multi-channel distribution network for CBD products in Europe.
• ICC Labs has the option to acquire the remaining 75% prior to the end of 2018.
_____________________________________________________________
Sources https://www.sedar.com/DisplayCompanyDocuments.do?lang=FR&issuerNo=00034719
https://www.icclabs.com/en/investors
This DD is for informational purposes only and does not constitute a recommendation to buy or sell any security.